Page last updated: 2024-08-21

pyrazines and bms345541

pyrazines has been researched along with bms345541 in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's4 (80.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bruserud, O; Hatfield, KJ; Kalland, KH; Kittang, AO; Oyan, AM; Reikvam, H1
Alsina, M; Beg, AA; Boulware, D; Chen, DT; Dalton, WS; Hazlehurst, LA; Mathews, L; Oliveira, V; Shain, KH; Villagra, A; Wang, X; Yarde, DN1
Bruserud, Ø; Ersvaer, E; Hatfield, KJ; Kittang, AO; Lassalle, P; Reikvam, H1
Bosman, MC; Quax, WJ; Schuringa, JJ; Vellenga, E1
Anderson, KC; Hide, M; Hideshima, H; Hideshima, T; Ikeda, H; Iwasaki, A; Yoshida, Y1

Other Studies

5 other study(ies) available for pyrazines and bms345541

ArticleYear
Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation.
    European journal of haematology, 2010, Volume: 84, Issue:3

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angiopoietin-2; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cells, Cultured; Chemokines; Coculture Techniques; Culture Media, Serum-Free; Cytarabine; Diterpenes; Endothelial Cells; Female; Humans; Imidazoles; Leukemia, Myeloid; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Middle Aged; Neoplasm Proteins; NF-kappa B; Protease Inhibitors; Pyrazines; Quinoxalines; Receptor, TIE-2; Recombinant Proteins; Tissue Inhibitor of Metalloproteinases; Tumor Cells, Cultured

2010
Targeting the Fanconi anemia/BRCA pathway circumvents drug resistance in multiple myeloma.
    Cancer research, 2009, Dec-15, Volume: 69, Issue:24

    Topics: Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Fanconi Anemia; Fanconi Anemia Complementation Group D2 Protein; Gene Expression; Humans; Imidazoles; Melphalan; Multiple Myeloma; NF-kappa B; Pyrazines; Quinoxalines; Transcription Factor RelB

2009
Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release.
    Expert opinion on investigational drugs, 2010, Volume: 19, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-1; Angiopoietin-2; Antibodies; Boronic Acids; Bortezomib; Cell Proliferation; Cells, Cultured; Coculture Techniques; Endothelial Cells; Female; Fibroblasts; Hepatocyte Growth Factor; Humans; Imidazoles; Interleukin-8; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Proteins; Osteoblasts; Proteoglycans; Pyrazines; Quinoxalines; Receptor Cross-Talk; Receptor, TIE-2; Signal Transduction

2010
Bortezomib sensitivity of acute myeloid leukemia CD34(+) cells can be enhanced by targeting the persisting activity of NF-κB and the accumulation of MCL-1.
    Experimental hematology, 2013, Volume: 41, Issue:6

    Topics: Antigens, CD34; Boronic Acids; Bortezomib; Coculture Techniques; Drug Resistance, Neoplasm; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; I-kappa B Kinase; Imidazoles; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplastic Stem Cells; NF-kappa B; Primary Cell Culture; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Quinoxalines; Recombinant Proteins; RNA, Small Interfering; Stromal Cells; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured

2013
IKKβ inhibitor in combination with bortezomib induces cytotoxicity in breast cancer cells.
    International journal of oncology, 2014, Volume: 44, Issue:4

    Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; I-kappa B Kinase; I-kappa B Proteins; Imidazoles; MCF-7 Cells; NF-KappaB Inhibitor alpha; Phosphorylation; Pyrazines; Quinoxalines; Transcription Factor RelA

2014